
Charles V Pollack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2976638/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Idarucizumab for Dabigatran Reversal. New England Journal of Medicine, 2015, 373, 511-520.	13.9	1,419
2	Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction. Circulation, 2009, 119, 1873-1882.	1.6	876
3	Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. New England Journal of Medicine, 2017, 377, 431-441.	13.9	858
4	Clinical Characteristics, Management, and Outcomes of Patients Diagnosed With Acute Pulmonary Embolism in the Emergency Department. Journal of the American College of Cardiology, 2011, 57, 700-706.	1.2	438
5	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	1.2	285
6	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet, The, 2011, 378, 693-703.	6.3	264
7	The Association Between Emergency Department Crowding and Adverse Cardiovascular Outcomes in Patients with Chest Pain. Academic Emergency Medicine, 2009, 16, 617-625.	0.8	247
8	Application of the TIMI Risk Score for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome to an Unselected Emergency Department Chest Pain Population. Academic Emergency Medicine, 2006, 13, 13-18.	0.8	218
9	Acute Clopidogrel Use and Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2006, 48, 281-286.	1.2	179
10	Recent Trends in the Care of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Archives of Internal Medicine, 2006, 166, 2027.	4.3	153
11	Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. Academic Emergency Medicine, 2002, 9, 1146-1155.	0.8	137
12	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis, 2015, 114, 198-205.	1.8	132
13	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. New England Journal of Medicine, 2019, 380, 1825-1833.	13.9	96
14	Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Practice Guidelines for Management and Care Transitions in the Emergency Department and Hospital. Journal of Emergency Medicine, 2015, 48, 508-519.	0.3	88
15	Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non–ST-segment elevation acute coronary syndrome. American Heart Journal, 2013, 165, 918-925.e2.	1.2	87
16	2007 Update to the ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. Annals of Emergency Medicine, 2008, 51, 591-606.	0.3	84
17	Clevidipine, an Intravenous Dihydropyridine Calcium Channel Blocker, Is Safe and Effective for the Treatment of Patients With Acute Severe Hypertension. Annals of Emergency Medicine, 2009, 53, 329-338.	0.3	84
18	A Prospective Multicenter Study of Patient Factors Associated With Hospital Admission From the Emergency Department Among Children With Acute Asthma. JAMA Pediatrics, 2002, 156, 934.	3.6	63

3

#	Article	IF	CITATIONS
19	Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry. American Journal of Emergency Medicine, 2012, 30, 1774-1781.	0.7	60
20	2007 Focused Update to the ACC/AHA Guidelines for the Management of Patients With ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. Annals of Emergency Medicine, 2008, 52, 344-355.e1.	0.3	48
21	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Annals of Emergency Medicine, 2020, 76, 470-485.	0.3	46
22	2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: Implications for emergency department practice. Annals of Emergency Medicine, 2003, 41, 355-369.	0.3	44
23	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Critical Care, 2016, 20, 115.	2.5	40
24	Unfractionated heparin dosing and risk of major bleeding in non–ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 156, 209-215.	1.2	39
25	Early Glycoprotein IIb/IIIa Inhibitor Use for Non-ST-segment Elevation Acute Coronary Syndrome: Patient Selection and Associated Treatment Patterns. Academic Emergency Medicine, 2005, 12, 431-438.	0.8	37
26	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation, 2019, 139, 748-756.	1.6	36
27	Idarucizumab for dabigatran overdose. Clinical Toxicology, 2016, 54, 644-646.	0.8	30
28	Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively. Circulation, 2017, 136, 1895-1907.	1.6	29
29	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. Annals of Surgery, 2021, 274, e204-e211.	2.1	27
30	EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report. , 2020, 2, e0196.		27
31	A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?. American Journal of Emergency Medicine, 2020, 38, 1890-1903.	0.7	26
32	Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. The Cochrane Library, 2001, , CD003571.	1.5	24
33	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. Journal of the American College of Cardiology, 2019, 74, 1760-1768.	1.2	24
34	Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from) Tj ETQq0 0 0 rgB	T / @v erloc	k 20 Tf 50 13
35	Dabigatran Reversal with Idarucizumab. New England Journal of Medicine, 2017, 377, 1690-1692.	13.9	23

Creation and Implementation of an Outpatient Pathway for Atrial Fibrillation in the Emergency Department Setting: Results of an Expert Panel. Academic Emergency Medicine, 2018, 25, 1065-1075. 36 0.8 22

#	Article	IF	CITATIONS
37	Managing Bleeding in Anticoagulated Patients in the Emergency Care Setting. Journal of Emergency Medicine, 2013, 45, 467-477.	0.3	21
38	Priority Considerations for Medicinal Cannabis-Related Research. Cannabis and Cannabinoid Research, 2019, 4, 139-157.	1.5	21
39	Prognostic Value of Symptoms during a Normal or Nonspecific Electrocardiogram in Emergency Department Patients with Potential Acute Coronary Syndrome. Academic Emergency Medicine, 2006, 13, 1034-1039.	0.8	19
40	New oral anticoagulants in the ED setting: a review. American Journal of Emergency Medicine, 2012, 30, 2046-2054.	0.7	19
41	Prognostic Value of Troponins in Patients with Nonâ€STâ€segment Elevation Acute Coronary Syndromes and Chronic Kidney Disease. Clinical Cardiology, 2008, 31, 125-129.	0.7	18
42	Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Academic Emergency Medicine, 2016, 23, 1280-1286.	0.8	18
43	Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. Critical Pathways in Cardiology, 2009, 8, 29-33.	0.2	17
44	Advanced Management of Acute Iliofemoral Deep Venous Thrombosis: Emergency Department and Beyond. Annals of Emergency Medicine, 2011, 57, 590-599.	0.3	17
45	The Usage Patterns of Cardiac Bedside Markers Employing Pointâ€ofâ€Care Testing for Troponin in Nonâ€STâ€Segment Elevation Acute Coronary Syndrome: Results from CRUSADE. Clinical Cardiology, 2009, 32, 498-505.	0.7	16
46	Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hospital Practice (1995), 2015, 43, 85-93.	0.5	16
47	Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–STâ€segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology, 2017, 40, 390-398.	0.7	16
48	Patientâ€reported Outcomes from A National, Prospective, Observational Study of Emergency Department Acute Pain Management With an Intranasal Nonsteroidal Antiâ€inflammatory Drug, Opioids, or Both. Academic Emergency Medicine, 2016, 23, 331-341.	0.8	15
49	Interrater Reliability of Criteria Used in Assessing Blunt Head Injury Patients for Intracranial Injuries. Academic Emergency Medicine, 2003, 10, 830-835.	0.8	13
50	Evidence Supporting Idarucizumab for the Reversal of Dabigatran. American Journal of Medicine, 2016, 129, S73-S79.	0.6	12
51	Can Electrocardiographic Criteria Predict Adverse Cardiac Events and Positive Cardiac Markers?. Academic Emergency Medicine, 2003, 10, 205-210.	0.8	11
52	Antiplatelet Therapy in Acute Coronary Syndromes: The Emergency Physician's Perspective. Journal of Emergency Medicine, 2008, 35, 5-13.	0.3	11
53	Emergency Medicine and Hospital Medicine: A Call for Collaboration. American Journal of Medicine, 2012, 125, 826.e1-826.e6.	0.6	11
54	Improving acute pain management in emergency medicine. Hospital Practice (1995), 2015, 43, 36-45.	0.5	11

#	Article	IF	CITATIONS
55	Evidence supporting idarucizumab for the reversal of dabigatran. American Journal of Emergency Medicine, 2016, 34, 33-38.	0.7	11
56	Emergency Medicine and Hospital Medicine: A Call forÂCollaboration. Journal of Emergency Medicine, 2012, 43, 328-334.	0.3	10
57	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. Angiology, 2017, 68, 29-39.	0.8	10
58	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. American Heart Journal, 2015, 170, 778-786.	1.2	9
59	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. American Journal of Emergency Medicine, 2020, 38, 1163-1170.	0.7	9
60	Contemporary NSTEMI management: the role of the hospitalist. Hospital Practice (1995), 2020, 48, 1-11.	0.5	9
61	Introduction to direct oral anticoagulants and rationale for specific reversal agents. American Journal of Emergency Medicine, 2016, 34, 1-2.	0.7	8
62	ldentification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment. Clinical Therapeutics, 2016, 38, 531-544.e9.	1.1	8
63	Wireless Cardiac Event Alert Monitoring is Feasible and Effective in the Emergency Department and Adjacent Waiting Areas. Critical Pathways in Cardiology, 2009, 8, 7-11.	0.2	7
64	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ,,¢ study. Journal of Medical Economics, 2017, 20, 435-442.	1.0	7
65	Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. Circulation: Cardiovascular Interventions, 2018, 11, e006084.	1.4	7
66	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e009759.	1.4	7
67	Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. Journal of Thrombosis and Haemostasis, 2019, 17, 1319-1328.	1.9	5
68	Early Treatment for Non‣Tâ€Segment Elevation Acute Coronary Syndrome Is Associated with Appropriate Discharge Care. Clinical Cardiology, 2009, 32, 519-525.	0.7	4
69	Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. Journal of Interventional Cardiology. 2011. 24. 119-136.	0.5	4
70	The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. American Journal of Emergency Medicine, 2014, 32, 1526-1533.	0.7	4
71	The Medical Management of Acute Coronary Syndromes and Potential Roles for New Antithrombotic Agents. Journal of Emergency Medicine, 2008, 34, 417-428.	0.3	3
72	Utility of platelet adp receptor antagonism in the emergency department: a review. Journal of Emergency Medicine, 2003, 24, 45-54.	0.3	2

#	Article	IF	CITATIONS
73	Emerging Oral Antiplatelet Therapies for Acute Coronary Syndromes. Hospital Practice (1995), 2010, 38, 29-37.	0.5	2
74	Atypical is becoming typical in ST-elevation myocardial infarction presentation, but delays persist for women. American Heart Journal, 2013, 166, 804-805.	1.2	2
75	Evidence for Basal–Bolus Insulin Versus Slide Scale Insulin. Current Emergency and Hospital Medicine Reports, 2014, 2, 26-34.	0.6	2
76	Variation Between Physicians and Mid-level Providers in Opioid Treatment for Musculoskeletal Pain in the Emergency Department. Journal of Emergency Medicine, 2015, 49, 415-423.	0.3	2
77	Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal Agents. American Journal of Medicine, 2016, 129, S31-S32.	0.6	2
78	Pharmacological and mechanical revascularization strategies in STEMI: integration of the two approaches. Journal of Invasive Cardiology, 2008, 20, 231-8.	0.4	2
79	Influence of Clinical Trial Participation on Subsequent Antithrombin Use. Clinical Cardiology, 2010, 33, E49-55.	0.7	1
80	Long-term impact of routine versus invasive ACS management. Nature Reviews Cardiology, 2010, 7, 544-546.	6.1	1
81	Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good. American Journal of Emergency Medicine, 2013, 31, 1408-1409.	0.7	1
82	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 76-89.	0.6	1
83	Dabigatran-related coagulopathy: when can we assume the effect has "worn off�. American Journal of Emergency Medicine, 2014, 32, 1433-1434.	0.7	1
84	Balancing Anti-thrombotic Efficacy and Bleeding Risk in the Contemporary Management of Venous Thromboembolism. Current Emergency and Hospital Medicine Reports, 2015, 3, 89-99.	0.6	1
85	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	0.7	1
86	Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why?. American Journal of Cardiology, 2021, 144, S10-S14.	0.7	1
87	Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Critical Pathways in Cardiology, 2020, 19, 166-172.	0.2	1
88	ED to catheterization laboratory: a roundtable integrating trials with practice. American Journal of Emergency Medicine, 2011, 29, 1203-1216.	0.7	0
89	Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 21-32.	0.4	0
90	Cardiovascular Risk in Diabetes Mellitus: Cause and Effect. Current Emergency and Hospital Medicine Reports, 2014, 2, 16-25.	0.6	0

#	Article	IF	CITATIONS
91	The Impact of Risk Stratification of Venous Thromboembolism on Complexity and Site of Management. Current Emergency and Hospital Medicine Reports, 2015, 3, 100-108.	0.6	ο
92	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	1.3	0
93	Antidotes for Bleeding Caused by Novel Oral Anticoagulants. Circulation, 2016, 133, e18-9.	1.6	Ο
94	ISSUE INTRODUCTION: The Diminishing Role of Aspirin in Cardiovascular Medicine: A Special Supplement to The American Journal of Cardiology. American Journal of Cardiology, 2021, 144, S1.	0.7	0
95	Higher daily pain severity after emergency department visits is associated with lower return-to-work rates. American Journal of Emergency Medicine, 2021, 45, 48-53.	0.7	Ο
96	New Functional Imaging Technology to Differentiate between Chronic Obstructive Pulmonary Disease and Heart Failure. Western Journal of Emergency Medicine, 2011, 12, 17-8.	0.6	0